The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The study will now proceed with the completion of regularly scheduled mammograms and follow-up on all participants...
Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL?
Late relapse of diffuse large B-cell lymphoma (DLBCL) may represent a new lymphoma arising from a common precursor cell that is essentially chemotherapy-naive. Treatment with curative intent using a second-line regimen like R-CHOP (rituximab cyclophosphamide, doxorubicin, prednisone, and...
Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL
A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary...
Predicting Response to KRAS G12C Inhibitors in NSCLC
Researchers may have uncovered a novel strategy to help predict how well patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) will respond to new therapies, according to a recent study published by Kato et al in Clinical Cancer Research.
Study Methods and Results
Researchers developed ...
Rising Advanced Prostate Cancer Rates in California Follow Changes to Recommendations
The incidence of advanced prostate cancer rose and the mortality rate plateaued in most regions across the state of California following the decision to cease routinely screening all men for the disease, according to a recent study published by Van Blarigan et al in JAMA Network Open. The findings...
Trastuzumab/Pertuzumab Plus Eribulin or Taxane in Locally Advanced or Metastatic Breast Cancer
In a Japanese noninferiority phase III trial (EMERALD) reported in the Journal of Clinical Oncology, Yamashita et al found that the addition of eribulin to trastuzumab/pertuzumab (HP) was noninferior in progression-free survival vs the addition of a taxane to HP in the first-line treatment of...
FDA Approves First Companion Diagnostic to Identify Patients With Metastatic Breast Cancer Eligible for T-DXd
The U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone receptor (HR)-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with fam-trastuzumab...
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
Salpingectomy During Other Abdominal Surgeries May Lower Ovarian Cancer Risk
Fallopian tube removal performed during other abdominal surgeries could reduce the risk of ovarian cancer incidence among women who have already completed their families, according to a recent study published by Kather et al in PLOS Medicine.
Background
Ovarian cancer is the third most common...
Chemotherapy Linked to Chronic Neuropathy for 4 in Every 10 Patients: Global Analysis Results
Worldwide, cancer chemotherapy is linked to chronic painful neuropathy for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the available evidence published by D’Souza et al in Regional Anesthesia & Pain Medicine.
Notwithstanding wide regional...
Thermal Ablation vs Surgical Resection of Small Resectable Colorectal Liver Metastases
In an interim analysis of a phase III noninferiority trial (COLLISION) reported in The Lancet Oncology, van der Lei et al found that thermal ablation was noninferior to surgical resection in terms of overall survival in patients with small resectable colorectal liver metastases.
Study Details
In...
Addition of Bevacizumab to Pembrolizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
In a Singaporean phase II trial reported in The Lancet Oncology, Chong et al found that the addition of bevacizumab to pembrolizumab improved objective response rate in patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Study Details
In the open-label trial, 48...
Cancer Symptoms Mistaken for Pregnancy Symptoms Could Lead to Delays in Cancer Diagnosis
Misdiagnosing cancer symptoms as normal pregnancy-related changes among pregnant individuals could lead to delays in treatment, according to a recent study published by Marcu et al in the British Journal of General Practice.
Study Methods and Results
In the study, researchers recruited 20 women...
Hereditary Ovarian Cancer Risk: Unlocking New Insights
Researchers have uncovered new heredity genes that may contribute to an increased risk of developing high-grade serous ovarian cancer, according to a recent study published by Subramanian et al in npj Genomic Medicine.
Background
High-grade serous ovarian cancer is one of the most prevalent and...
CheckMate 7FL: Neoadjuvant Immunochemotherapy in ER-Positive, HER2-Negative Breast Cancer
A phase III trial has shown adding the PD-1 inhibitor nivolumab to anthracycline- and taxane-based chemotherapy that patients receive ahead of surgery may improve breast cancer cure rates.
CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer,...
TACE and Durvalumab/Bevacizumab in Unresectable HCC
In the phase III EMERALD-1 trial reported in The Lancet, Sangro et al found that transarterial chemoembolization (TACE) with durvalumab/bevacizumab improved progression-free survival vs placebo in patients with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Study Details
...
Does Brain MRI Surveillance Benefit Asymptomatic Patients With Stage IV Breast Cancer?
Researchers have found that asymptomatic brain metastases may be more common in patients with stage IV breast cancer than previously understood, according to a recent study published by Ahmed et al in Neuro-Oncology. The findings suggest that physicians may need to reconsider current screening...
BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis
The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) ...
Perioperative Chemotherapy vs Preoperative Chemoradiotherapy in Resectable Locally Advanced Esophageal Carcinoma
In a German phase III trial (ESOPEC) reported in The New England Journal of Medicine, Hoeppner et al found that perioperative chemotherapy with fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) improved overall survival vs preoperative chemoradiotherapy in patients undergoing surgery for locally ...
Tiragolumab Plus Atezolizumab/Bevacizumab in Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma
In a phase Ib-II study (MORPHEUS-Liver) reported in The Lancet Oncology, Finn et al found that the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab/bevacizumab improved objective response rate in patients with unresectable, locally advanced, or metastatic hepatocellular...
Expediting Cancer Diagnoses With Acoustofluidics?
A novel system using standing surface acoustic waves may effectively and precisely separate circulating tumor cells from red blood cells, according to a novel study published by Kouhkord and Naserifar in the Physics of Fluids.
Background
Cancer accounted for nearly 10 million deaths in...
Talimogene Laherparepvec May Effectively Reduce Basal Cell Carcinoma Size Prior to Surgical Resection
Treatment with the oncolytic virus talimogene laherparepvec may be effective in patients with basal cell carcinoma, according to a novel study published by Ressler et al in Nature Cancer.
Background
Although basal cell carcinoma—which typically occurs in chronically sun-exposed areas such as the...
Fecal Microbiota Transplantation Following ASCT
Oral fecal microbiota transplantation may be a feasible and safe option to prevent graft-vs-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant (ASCT), according to a recent report published by Reddi et al in Nature Communications. The findings built on ...
Transplant-Free Treatment Approach in Relapsed Classical Hodgkin Lymphoma in Children and Adolescents and Young Adults
As reported in JAMA Oncology by Daw et al, findings in a cohort of the phase II CheckMate 744 trial indicated good outcomes with a response-adapted, transplantation-free treatment approach in children and adolescents and young adults (AYAs) with low-risk relapsed classical Hodgkin lymphoma (HL).
...
Nivolumab Plus AVD as Front-Line Therapy in Older Adults With Classical Hodgkin Lymphoma
In a phase I/II trial reported in the Journal of Clinical Oncology, Torka et al found that the addition of nivolumab to standard doxorubicin, vinblastine, and dacarbazine (N-AVD) was “highly effective” as front-line treatment for patients aged ≥ 60 with classical Hodgkin lymphoma.
Study Details
...
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma
On January 16, the U.S. Food and Drug Administration (FDA) granted traditional approval to the Bruton’s tyrosine kinase inhibitor acalabrutinib (Calquence) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem...
CAR T-Cell Therapy for Relapsed/Refractory Mantle Cell Lymphoma: ZUMA-2
Long-term follow-up of patients in ZUMA-2 cohorts 1 and 2 showed that 39% of patients with relapsed/refractory mantle cell lymphoma were alive after 5 years; patients in these cohorts received brexucabtagene autoleucel, the only chimeric antigen receptor (CAR) T-cell therapy to have 5-year...
FDA Highlights Importance of DPD Deficiency Discussions With Patients Prior to Capecitabine or Fluorouracil Treatment
The U.S. Food and Drug Administration (FDA) has provided a safety announcement to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil related to the risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency.
Background
Fluoropyrimidines are a ...
UICC‘s New World Cancer Day Campaign Calls for Fundamental Shift in Cancer Care Delivery
The Union for International Cancer Control (UICC) has introduced the new 2025 to 2027 United by Unique campaign, calling for a fundamental shift in cancer care and health systems across the world toward a people-centered approach in light of World Cancer Day. World Cancer Day takes place on...
Young Patients With Cancer Living in Historic Redlined Neighborhoods Are Dying at Higher Rates Than Those in Nonredlined Areas
Studies have shown that adults living in historically redlined neighborhoods are less likely to be screened for breast, colorectal, and cervical cancers and have worse survival than those living in nonredlined areas. Redlining, a discriminatory, racist practice that began in the 1920s and 1930s in...
Neoadjuvant Nivolumab/Ipilimumab vs Chemotherapy in Resectable NSCLC
As reported in the Journal of Clinical Oncology by Awad et al, exploratory analysis of the comparison of neoadjuvant nivolumab/ipilimumab vs chemotherapy in the phase III CheckMate 816 trial found that nivolumab/ipilimumab was associated with numerically better event-free survival in patients with...
Early-Stage Classic Hodgkin Lymphoma
“It isn’t the mountains ahead to climb that wear you out; it’s the pebble in your shoe.”
—Muhammad Ali
Long-term survival in early-stage classic Hodgkin lymphoma (cHL) was first made possible by the introduction of the mantle and inverted Y fields of radiotherapy in the 1960s. The addition of...
Addition of Cetuximab to Postoperative Radiotherapy in Intermediate-Risk Head and Neck Cancer
In a phase III trial (NRG/RTOG 0920) reported in Journal of Clinical Oncology, Machtay et al found that the addition of cetuximab to postoperative radiotherapy significantly improved disease-free survival—but not overall survival—in patients with completely resected, intermediate-risk, squamous...
Pinpointing Contributing Factors in Response to Posttransplant Donor Lymphocyte Infusion in Patients With AML
Researchers have identified factors that could determine whether donor lymphocyte infusion—a type of adoptive cell therapy—will result in remission among patients with acute myeloid leukemia (AML) who have relapsed following allogeneic hematopoietic stem cell transplant (HSCT), according to a...
Clearance of Driver Mutations after Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis
In a German single-center study reported in The New England Journal of Medicine, Gagelmann et al determined that clearance of driver mutations after allogeneic hematopoietic stem-cell transplantation was associated with better outcomes in patients with myelofibrosis.
Study Details
The study...
Anatomic Lung Resection May Be Linked to Improved Survival in Early-Stage NSCLC
Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival in patients with early-stage non–small cell lung cancer (NSCLC) compared with wedge resection, according to new findings presented at the 2025 Society of Thoracic Surgeons (STS) Annual...
Study Finds Therapeutic Vaccine Targeting HPV16 Is Safe and Effective in Eradicating Precancerous Cervical Lesions
The investigational therapeutic vaccine Vvax001 was found to be safe and showed preliminary clinical effectiveness in a phase II clinical trial of patients with HPV16-positive grade 3 cervical intraepithelial neoplasia. If confirmed in a phase III trial, the vaccine may provide a nonsurgical option ...
T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ...
Use of Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia
In a German phase III trial (CLL12), reported in the Journal of Clinical Oncology, Langerbeins et al found that ibrutinib prolonged the time to symptomatic disease in patients with early-stage chronic lymphocytic leukemia (CLL) vs placebo. However, no differences in overall survival were observed.
...
Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer
First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) chemotherapy regimen may be effective in patients with BRAF V600E–mutated metastatic colorectal cancer, according to recent findings presented by Kopetz et ...
Melanoma Among Adult Survivors of Childhood Cancer
In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Rotz et al found that adult survivors of childhood cancers had a twofold increased risk of developing melanoma compared with the general population. Additionally, those with an invasive melanoma had a more...
New Findings on Aspirin and Risk of Colorectal Cancer Recurrence
According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily after treatment ends may reduce the risk of cancer recurrence in patients with cancers that harbor a PI3K mutation. These mutations are common to many types ...
EULAR: Balancing Treatment Risks for Inflammatory Arthritis and Cancer
The European Alliance of Associations for Rheumatology (EULAR) introduced new points to consider surrounding the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer, according to recent recommendations published by Sebbag et al in the Annals of the...
New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer
Previous research has shown that nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors, may reduce the risk of developing colon cancer. A recent CALGB/SWOG study revealed that adding celecoxib to FOLFOX chemotherapy improved disease-free survival in patients with...
Addition of Cyclophosphamide to Posttransplantation GVHD Prophylaxis
As reported in the Journal of Clinical Oncology by Holtan et al, the addition of cyclophosphamide to posttransplantation graft-vs-host disease (GVHD) prophylaxis with tacrolimus and mycophenolate mofetil was associated with improved patient-reported outcomes in the phase III BMT CTN 1703 trial in...
Advanced NSCLC With Brain Metastases: Potential Novel Therapeutic Option
In a Chinese phase II study (C-Brain) reported in The Lancet Oncology, Xu et al found that brain radiotherapy in combination with camrelizumab and platinum-doublet chemotherapy produced “promising” results in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with brain...
Addition of Lenvatinib/Pembrolizumab to TACE in Unresectable Nonmetastatic HCC
As reported in The Lancet by Kudo et al, the phase III LEAP-012 trial has shown a significant progression-free survival benefit with the addition of lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) in patients with unresectable nonmetastatic hepatocellular carcinoma (HCC). A...
New Study Highlights Financial Burden of Medical Equipment on Cancer Survivors
Investigators may have uncovered the financial burden of different medical services on cancer survivors, according to a recent study published by Jafri et al in JAMA Network Open.
Background
Although the economic challenges faced by patients with cancer as a result of health-care costs are well...
Muscular Strength, Cardiorespiratory Fitness May Be Linked to Lower Risk of Mortality in Patients With Cancer
Muscular strength and cardiorespiratory fitness may be associated with a lower risk of all-cause mortality in patients with cancer, according to a recent study published by Bettariga et al in the British Journal of Sports Medicine. The findings indicated that a tailored exercise regimen may improve ...
Genomic Classifier Tests May Influence Treatment Decisions in Prostate Cancer Despite Lack of Evidence for Long-Term Outcomes
Although genomic classifier tests may influence risk classifications or treatment decisions in patients with localized prostate cancer, there is a need for more data to better understand cost effectiveness, clinical utility, and their impact on racial and ethnic groups—particularly Black men,
Effect of KRAS Mutation Status on Treatment Outcomes in Metastatic Pancreatic Adenocarcinoma
In a study reported in JAMA Network Open, Norton et al found that KRAS G12D and G12V mutations were associated with worse outcomes compared with KRAS wild-type in patients with metastatic pancreatic adenocarcinoma.
Study Details
The retrospective cohort study used data from a nationwide...
Talquetamab Plus Teclistamab in Relapsed or Refractory Multiple Myeloma
In a phase Ib-II study (RedirecTT-1) reported in The New England Journal of Medicine, Cohen et al found that the combination of the bispecific antibodies talquetamab (anti–G protein-coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) was associated with a...
Telephone-Based Therapy May Reduce Fatigue Interference With Functioning in Metastatic Breast Cancer Survivors
Telephone-delivered acceptance and commitment therapy may be effective in reducing the interference of fatigue with functioning and improving the quality of life among survivors of metastatic breast cancer, according to a recent study published by Mosher et al in the Journal of Clinical Oncology.
...
Imlunestrant Alone or With Abemaciclib: An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer
The investigational next-generation oral selective estrogen receptor degrader (SERD) imlunestrant improved progression-free survival both as monotherapy in patients with ESR1 mutations and in combination with the CDK4/6 inhibitor abemaciclib regardless of ESR1 mutational status in patients with...
ChatGPT Has Limitations in Clinical Utility for Colorectal Cancer but May Be Useful for Patient Education
A study evaluating ChatGPT’s ability to accurately respond to patient inquiries regarding colon cancer by comparing its responses with assessments from expert clinical oncologists found that questions about symptoms, prevention, and screening for the disease were highly accurate; however, responses ...
Everolimus/Lanreotide vs Everolimus in Gastroenteropancreatic Neuroendocrine Tumors
A recent study found that a combination of the mTOR inhibitor everolimus and the hormone-blocking drug lanreotide extended progression-free survival compared with everolimus alone for people with some types of neuroendocrine tumors in the pancreas or gastrointestinal tract. The research will be...
Does a New Blood-Based Screening Test Accurately Detect Colorectal Cancer Risk?
Colorectal cancer is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease.
Although screening for the cancer through colonoscopy or sigmoidoscopy is effective in detecting the disease, nearly
ASCO Thanks Drs. Bertagnolli, Rathmell for Their Service Leading NIH, NCI
ASCO has applauded Monica M. Bertagnolli, MD, FASC, FASCO, for her service as the 17th Director of the National Institutes of Health (NIH) and Kimryn Rathmell, MD, PhD, for her work as the 17th Director of the National Cancer Institute (NCI).
“ASCO would like to extend our deepest gratitude to Dr. ...
New Study Identifies Potential Dose-Dependent Relationship Among Alcohol Consumption, HBV-Associated Cirrhosis, Hepatocellular Carcinoma
Investigators may have established a dose-dependent model of alcohol consumption on the risks of hepatitis B virus (HBV)-associated cirrhosis and hepatocellular carcinoma, according to a recent study published by Wu et al in the Journal of Clinical and Translational Hepatology. The quantitative...
FDA Approves Datopotamab Deruxtecan-dlnk for Advanced HR-Positive, HER2-Negative Breast Cancer
On January 17, the U.S. Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk (Datroway), a TROP-2–directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC1+, or...
FDA Approves Sotorasib With Panitumumab for KRAS G12C–Mutated Colorectal Cancer
On January 16, the U.S. Food and Drug Administration (FDA) approved the KRAS G12C inhibitor sotorasib (Lumakras) with the monoclonal antibody panitumumab (Vectibix) for adult patients with KRAS G12C–mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior ...
Fulvestrant vs Anastrozole in Endocrine Therapy–Naive, HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by John F.R. Robertson, PhD, and colleagues, the final overall survival analysis of the phase III FALCON trial showed no difference between fulvestrant vs anastrozole in patients with endocrine therapy–naive, hormone receptor–positive, HER2-negative...
AACR Expresses Sincere Appreciation After NIH Director Monica M. Bertagnolli, MD, Steps Down
The American Association for Cancer Research (AACR) expressed its gratitude to Monica M. Bertagnolli, MD, for her outstanding service to the United States during her 14-month tenure as Director of the National Institutes of Health (NIH).
Background
Dr. Bertagnolli recently announced that she will ...
Risks of Preterm Birth, Low Birth Weight, Birth Defects Among Children Born to Young Men With Cancer
The risk of having children who experience preterm birth and low birth weight—but not birth defects—may be increased among male adolescents and young adults with cancer, according to a recent study published by Murphy et al in the Journal of the National Cancer Institute.
Background
Prior...
Trastuzumab/Pertuzumab vs Cetuximab/Irinotecan in RAS/BRAF Wild-Type HER2-Positive Metastatic Colorectal Cancer
In a phase II trial (S1613) reported in the Journal of Clinical Oncology, Raghav et al found no difference in progression-free survival overall with trastuzumab/pertuzumab vs cetuximab/irinotecan in the second- or third-line treatment of RAS/BRAF wild-type HER2-positive metastatic colorectal...
ACS Annual Report: Cancer Mortality Rates Decline, but Challenges Remain
The findings in the American Cancer Society’s annual report, Cancer Statistics, 2025, show a mixed trend in cancer incidence and mortality rates. While cancer mortality declined by 34% from 1991 to 2022 in the United States—largely due to smoking reductions, earlier detection, and improved...
Exercise Therapy as Candidate Anticancer Strategy
Guest Editor’s Note: With growing evidence indicating that regular physical activity helps control cancer symptoms, oncology guidelines recommend exercise before, during, and after cancer treatment. Observational data also demonstrate a promising association between physical activity and favorable...
Extent and Impact of Primary MMRD in Gliomas Among Children and AYAs
In a cohort study reported in The Lancet Oncology, Negm et al found that primary mismatch repair deficiency (MMRD) was associated with poor outcomes in children, adolescents, and young adults with gliomas.
Study Details
In the study, clinical and molecular data were collected from children,...
Adjuvant T-DM1 in Patients With HER2-Positive Breast Cancer: Long-Term Results of the KATHERINE Trial
Adjuvant treatment with the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) may improve survival in patients with high-risk HER2-positive breast cancer and residual invasive disease, according to long-term findings from the phase III KATHERINE trial published by Geyer et al in The New...
MRI and Biopsy May Reduce Treatment Delays for Muscle-Invasive Urothelial Carcinoma
Multiparametric magnetic resonance imaging (MRI) and biopsy may speed up the time to correct treatment among patients with a muscle-invasive urothelial carcinoma, according to a recent study published by Bryan et al in the Journal of Clinical Oncology.
Background
Usual tests for muscle-invasive...
Monica Bertagnolli, MD, FACS, FASCO, Steps Down as NIH Director
On January 14, Monica Bertagnolli, MD, FACS, FASCO, announced that she was ending her tenure as the 17th Director of the National Institutes of Health (NIH). She began her role as Director on November 9, 2023.
Dr. Bertagnolli was the 16th Director of the National Cancer Institute, a role she...
FDA Proposes Significant Step to Reduce Nicotine Levels in Cigarettes, Tobacco Products
The U.S. Food and Drug Administration (FDA) issued a proposed rule that, if finalized, would make cigarettes and certain other combusted tobacco products minimally or nonaddictive by limiting the level of nicotine in those products. If the rule is finalized, the United States would be the first...
PFAS Contamination in Drinking Water May Be Linked to Several Rare Cancers
Investigators may have uncovered an association between manufactured per- and polyfluoroalkyl substances (PFAS) levels in drinking water and the incidence of certain digestive, endocrine, lung, oral, and pharyngeal cancers, according to a novel study published by Li et al in the Journal of Exposure ...
Novel Antibody-Drug Conjugate in Advanced Gastric/Gastroesophageal Junction Cancer
In a Chinese phase I trial (KYM901) reported in The Lancet Oncology, Ruan et al found that CMG901—a first-in-class claudin 18.2–targeting antibody-drug conjugate—had manageable toxicity and activity in patients with advanced gastric or gastroesophageal junction (GEJ) cancer. CMG901 comprises a...
Even Low Levels of ctDNA May Be Linked to Recurrence Risk in Early Lung Cancer, Study Finds
Lung cancer is the second most common cancer in the United States, but high recurrence rates persist for patients with early-stage disease. A recent study published by Black et al in Nature Medicine has found that even very low traces of circulating tumor DNA (ctDNA) may be linked to increased...
FDA Grants Orphan Drug Designation to New Agent for Pancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration has granted Orphan Drug designation to the investigational agent ELC-100 for the treatment of pancreatic neuroendocrine tumors, according to a press release from Elicera Therapeutics, the drug developer.
ELC-100 is an oncolytic virus–based therapy designed to...
Study Finds Travel Distance to Lung Cancer Screening Facilities Differs by Race and Ethnicity
Lung cancer is the second most common cancer, excluding skin cancer, diagnosed in men and women in the United States. And despite advances in treatment for the disease, which have led to improved survival rates, lung cancer remains the leading cause of cancer mortality in the United States, with...
Addition of Brentuximab Vedotin to Lenalidomide/Rituximab in Relapsed or Refractory DLBCL
In an interim analysis of a phase III trial (ECHELON-3) reported in the Journal of Clinical Oncology, Bartlett et al found that the addition of brentuximab vedotin (BV) to lenalidomide and rituximab improved overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma...
Potential of RAD51 Testing in Tailoring Treatment Strategies in Early Breast Cancer
The RAD51 biomarker may help to tailor treatment strategies in patients with early breast cancer, according to a recent study published by Villacampa et al in Clinical Cancer Research.
Background
“A key objective of research focused on early-stage breast cancer is to identify biomarkers that can...
Effects of Obesity on Survival Outcomes Following Cancer Diagnosis in Pediatric Patients
Pediatric patients with cancer who have obesity at the time of diagnosis may face an elevated risk of mortality, according to a recent study published by Sassine et al in Cancer.
Study Methods and Results
In the retrospective study, investigators examined data from the Cancer in Young People in...
AI May Enhance Cervical Cancer Detection
Artificial intelligence (AI) could improve screening for cervical cancer, enhancing accuracy and efficiency, according to a recent review article published by Wu et al in Cancer Biology & Medicine. The report, authored by a team of researchers from the Chinese Academy of Medical Sciences and...
Therapeutic De-escalation in Breast Cancer: Can Omitting Axillary Surgery Match Survival While Improving Patient Outcomes?
Omitting axillary surgery may be an option for some patients with early-stage breast cancer, according to a study reported by Reimer et al in The New England Journal of Medicine. Previous studies, such as the SOUND trial, have indicated that avoiding an axillary procedure in patients with small...
Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality
Although lung cancer and related cancer deaths decreased in the world’s 10 most populous countries from 1990 to 2019, these positive statistics may not address trends in mortality linked to tobacco use, air pollution, and asbestos exposure, according to a recent study published by Jani et al in...
NCCN Joins International Meeting to Improve Cancer Care in the Middle East North Africa Region
The National Comprehensive Cancer Network (NCCN) announced that the organization participated in a 2-day meeting at the Middle East North Africa (MENA)–NCCN Regional Coordinating Center.
Background
The MENA-NCCN Regional Coordinating Center is supported by the Ministry of National Guard Health...
Medicare Advantage vs Traditional Medicare: Cost Differences in Cancer Drugs
A new study examining the use of high-cost drugs among patients with colorectal cancer and non–small cell lung cancer (NSCLC) found those insured through Medicare Advantage received less expensive cancer drugs compared to others on traditional Medicare. The findings were published by Bradley et al...
Datopotamab Deruxtecan in Advanced or Metastatic NSCLC With Actionable Genomic Alterations
As reported in the Journal of Clinical Oncology by Sands et al, the phase II TROPION-Lung05 trial showed “encouraging activity” of datopotamab deruxtecan (Dato-DXd) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) with actionable genomic alterations whose disease progressed...
Former UNMC Cancer Center Director, Kenneth H. Cowan, MD, PhD, Dies at 77
Kenneth H. Cowan, MD, PhD, served for 24 years as Director of NCI-designated cancer center at the University of Nebraska Medical Center (UNMC), now called the Nebraska Medicine Fred & Pamela Buffett Cancer Center in Omaha. Dr. Cowan died on December 15, 2024, at the age of 77 years.
A native ...
Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found evidence of efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy and consolidative immunotherapy in patients with locally advanced non–small cell lung cancer...
Novel AI Platform May Help Identify Patients Likely to Benefit Most From Clinical Trials
Researchers have demonstrated that a novel artificial intelligence (AI)-based platform could aid physicians and patients in assessing the benefit from a particular therapy being tested in a clinical trial, according to a recent study published by Orcutt et al in Nature Medicine. The AI platform may ...
ORACLE Test May Predict Survival in Early Stages of Lung Cancer
The ORACLE test may be capable of predicting lung cancer survival at the point of diagnosis more effectively than currently used clinical risk factors, according to a recent study published by Biswas et al in Nature Cancer. The findings could help physicians make more informed treatment decisions...
Long-Term Follow-up of NRG258 Trial: Adjuvant Chemoradiation vs Chemotherapy in Locally Advanced Endometrial Carcinoma
As reported in the Journal of Clinical Oncology by Matei et al, the final overall survival analysis in the long-term follow-up of the phase III NRG258 trial has shown no difference between adjuvant chemoradiation (C-RT) vs chemotherapy (CT) in patients with locally advanced endometrial carcinoma....
Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Heinzerling et al found that primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemoradiotherapy (with or without adjuvant immunotherapy) was associated with activity in patients with locally advanced...
Adjuvant Dose-Dense vs Conventional Chemotherapy in Node-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Filho et al, 12-year follow-up of the CALBG (Alliance) C9741 trial has shown a sustained advantage of adjuvant dose-dense vs conventional chemotherapy in disease-free and overall survival in patients with node-positive breast cancer.
Study Details
...
Improvements in BRCA2 Testing Could Enhance Cancer Risk Assessment, Patient Care
Researchers may have advanced the understanding of genetic alterations in the BRCA2 gene, according to a recent study published by Huang et al in Nature. The findings could improve the accuracy of genetic testing and allow health-care professionals to offer more precise risk assessments and...
Novel Tool for Predicting Response to Immunotherapy in Melanoma Under Study
A team of scientists from the United Kingdom and the United States has discovered that the activity of macrophages may prove to be useful in predicting whether or not a patient with melanoma will respond to immunotherapy. Their findings, published in JCO Oncology Advances, may help clinicians to...
Mobility Patterns and Survival Disparities in Patients With Cancer
A recent study published in Health Data Science, conducted by Fengyu Wen, PhD, MPH, of the Institute of Medical Technology at Peking University Health Science Center; Luxia Zhang, MD, MPH, of the National Institute of Health Data Science at Peking University; and colleagues, revealed significant...
New Study Identifies Genes That Could Be Implicated in Glioblastoma in Adulthood
Researchers have discovered of a new type of stem cell in the brain that could lead to the development of more effective treatments in adult patients with glioblastoma, according to a recent study published by Wang et al in Nature. The finding could help explain how adult brain cells take advantage ...
Use of Denileukin Diftitox-cxdl in Relapsed or Refractory CTCL
In a registrational trial reported in the Journal of Clinical Oncology, Foss et al found that denileukin diftitox (DD)-cxdl—a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2—was active in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)....
Belzutifan Plus Cabozantinib as First-Line Treatment in Advanced Clear Cell Renal Cell Carcinoma
In a phase II trial (LITESPARK-003), reported in The Lancet Oncology, Choueiri et al found that the combination of belzutifan—a first-in-class HIF-2α inhibitor—and cabozantinib showed promising activity in the first-line treatment of patients with advanced clear cell renal cell carcinoma.
Study...
Belinda Avalos, MD, Begins Term as 2025 ASH President
Belinda Avalos, MD, Professor of Medicine and a senior advisor to the President of Atrium Health Levine Cancer, will serve as president of the American Society of Hematology (ASH) for a year-long term through December 2025.
Overview
Dr. Avalos is a physician-scientist with a special clinical...
Advertisement
Advertisement
Feb
Today In Oncology05
Advertisement
© 2025 HSP News Service, L.L.C.
